Antares Pharma to Present at the Rodman & Renshaw 19th Annual Global Investment Conference
September 05 2017 - 7:00AM
Antares Pharma, Inc. (NASDAQ:ATRS) today announced that Robert F.
Apple, President and Chief Executive Officer, will present at the
Rodman & Renshaw 19th Annual Global Investment Conference on
Monday, September 11, 2017 at 12:30 p.m. Eastern Time.
A live webcast of the presentation will be
available via the “Investor Information/Webcasts” page of the
Antares website, www.antarespharma.com. A replay of the webcast
will also be archived on Antares’ website for 90 days following the
presentation.
About Antares Pharma
Antares Pharma focuses on self-administered
parenteral pharmaceutical products. The Company’s product, OTREXUP®
(methotrexate) injection for subcutaneous use, is approved in the
U.S. for the treatment of adults with severe active rheumatoid
arthritis, children with active polyarticular juvenile idiopathic
arthritis and adults with severe recalcitrant psoriasis. The
Company’s product Sumatriptan Injection USP, is approved in the
U.S. for the acute treatment of migraine and cluster headache and
is distributed by Teva Pharmaceutical Industries, Ltd. (Teva).
Antares Pharma is also developing XYOSTED™ for testosterone
replacement therapy and has filed a New Drug Application with the
Food and Drug Administration. The Company's technology platforms
include VIBEX® disposable auto injectors, disposable multi-use pen
injectors and reusable needle-free injectors. Antares Pharma has
license, development and supply agreements with Teva that include
VIBEX® epinephrine, exenatide multi-dose pen, and teriparatide
multi-dose pen. Our reusable needle-free injector for use
with human growth hormone (hGH) is sold worldwide by Ferring
B.V. The Company is also working with AMAG Pharmaceuticals on
a subcutaneous method for administering Makena, a progesterone
product indicated for use in lowering the risk of pre-term
birth. For more information, visit www.antarespharma.com.
SAFE HARBOR STATEMENT UNDER THE PRIVATE
SECURITIES LITIGATION REFORM ACT OF 1995
This press release contains
forward-looking statements within the meaning of the safe harbor
provisions of the Private Securities Litigation Reform Act of
1995. Forward-looking statements are subject to certain risks
and uncertainties that can cause actual results to differ
materially from those described. Factors that may cause such
differences include, but are not limited to: U.S. Food and Drug
Administration (“FDA”) approval of the XYOSTED™ NDA and future
market acceptance and revenue for XYOSTED™; FDA approval of the
sNDA submitted by AMAG Pharmaceuticals for an auto injector for
Makena and future market acceptance and revenue of the same; the
outcome of the pending patent litigation between Teva
Pharmaceutical Industries, Ltd. (Teva) and Eli Lilly and Company
regarding the Teriparatide multi-dose pen; FDA action with respect
to Teva’s Abbreviated New Drug Application (“ANDA”) for the
Teriparatide multi-dose pen and the timing and approval, if any, by
the FDA of the same; Teva’s expectations about timing and approval
of the VIBEX® epinephrine pen ANDA by the FDA and potential product
launch of the same, the therapeutic equivalence rating thereof, and
any future revenue from the same; Teva’s ability to successfully
commercialize VIBEX® Sumatriptan Injection USP and the amount of
revenue from the same; FDA action with respect to Teva’s ANDA filed
for the Exenatide pen and future revenue from the same; continued
growth of prescriptions and sales of OTREXUP®; the timing and
results of research projects, clinical trials, and product
candidates in development; actions by the FDA or other regulatory
agencies with the respect to the Company’s products or product
candidates of its partners; continued growth in product,
development, licensing and royalty revenue; the Company’s ability
to obtain financial and other resources for its research,
development, clinical, and commercial activities and other
statements regarding matters that are not historical facts, and
involve predictions. These statements involve known and unknown
risks, uncertainties and other factors that may cause actual
results, performance, achievements or prospects to be materially
different from any future results, performance, achievements or
prospects expressed in or implied by such forward-looking
statements. In some cases you can identify forward-looking
statements by terminology such as ''may'', ''will'', ''should'',
''would'', ''expect'', ''intend'', ''plan'', ''anticipate'',
''believe'', ''estimate'', ''predict'', ''potential'', ''seem'',
''seek'', ''future'', ''continue'', or ''appear'' or the negative
of these terms or similar expressions, although not all
forward-looking statements contain these identifying words.
Additional information concerning these and other factors that may
cause actual results to differ materially from those anticipated in
the forward-looking statements is contained in the "Risk Factors"
section of the Company's Annual Report on Form 10-K for the year
ended December 31, 2016, and in the Company's other periodic
reports and filings with the Securities and Exchange
Commission. The Company cautions investors not to place undue
reliance on the forward-looking statements contained in this press
release. All forward-looking statements are based on information
currently available to the Company on the date hereof, and the
Company undertakes no obligation to revise or update these
forward-looking statements to reflect events or circumstances after
the date of this press release, except as required by
law.
Contact:
Jack Howarth
Vice President, Corporate Affairs
609-359-3016
jhowarth@antarespharma.com
Antares Pharma (NASDAQ:ATRS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Antares Pharma (NASDAQ:ATRS)
Historical Stock Chart
From Sep 2023 to Sep 2024